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Epithelial ovarian cancer is a devastating disease 
responsible for the deaths of 15,000 Americans 
per year, even more than melanoma or brain 
tumors (Jemal et al., 2009). Independent studies 
have demonstrated that in the ovarian carci-
noma microenvironment, T cells (and only they) 
can spontaneously exert clinically relevant pres-
sure against tumor progression (Zhang et al., 2003; 
Sato et al., 2005; Hamanishi et al., 2007). How-
ever, as the dismal statistics show, immune pressure 
against established tumors is insufficient. In part, 
this is because when tumors become clinically 
symptomatic, they have already overcome the 
immune system through multiple complemen-
tary mechanisms. The “cancer immunoediting” 
hypothesis, supported by recent experimental and 
clinical evidence, provides a frame to understand 
this process (Schreiber et al., 2011). The model 
implies that all symptomatic tumors represent a 
failure of the immune system. Recent studies 
have postulated that tumors can be kept in check 
for long periods, through a dynamic balance 
that results in the progressive loss of immunoge-
nicity by tumor cells. However, emerging clinical 
evidence from multiple trials blocking common 
immunosuppressive checkpoints (such as CTLA4 
or PD-1) indicates that preventing tumor-induced 
T cell paralysis restores protective immunity 
against established cancers, implying that advanced 
tumors remain somewhat immunogenic. Based 
on multiple lines of evidence, the model has 
recently evolved to include the role of immuno-
suppression in the tumor microenvironment in 
this process. However, the relative contribution of 
individual microenvironmental populations to 
suppress or support the capacity of tumors to 
expand and their dynamics remains unclear.
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We characterized the initiation and evolution of the immune response against a new induc-
ible p53-dependent model of aggressive ovarian carcinoma that recapitulates the leukocyte 
infiltrates and cytokine milieu of advanced human tumors. Unlike other models that initiate 
tumors before the development of a mature immune system, we detect measurable anti-
tumor immunity from very early stages, which is driven by infiltrating dendritic cells (DCs) 
and prevents steady tumor growth for prolonged periods. Coinciding with a phenotypic 
switch in expanding DC infiltrates, tumors aggressively progress to terminal disease in a 
comparatively short time. Notably, tumor cells remain immunogenic at advanced stages, but 
anti-tumor T cells become less responsive, whereas their enduring activity is abrogated by 
different microenvironmental immunosuppressive DCs. Correspondingly, depleting DCs early 
in the disease course accelerates tumor expansion, but DC depletion at advanced stages 
significantly delays aggressive malignant progression. Our results indicate that phenotypi-
cally divergent DCs drive both immunosurveillance and accelerated malignant growth. We 
provide experimental support for the cancer immunoediting hypothesis, but we also show 
that aggressive cancer progression after a comparatively long latency period is primarily 
driven by the mobilization of immunosuppressive microenvironmental leukocytes, rather 
than loss of tumor immunogenicity.
© 2012 Scarlett et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommer-
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we used a previously 
described technique 
(Flesken-Nikitin et al., 
2003; Dinulescu et al., 
2005), based on the delivery of recombinant adenoviruses ex-
pressing Cre recombinase into the ovarian bursal cavity. Ablation 
of only p53—the hallmark of malignancy in human ovarian 
carcinoma (Bernardini et al., 2010)—did not result in any ob-
vious carcinogenic event >200 d after induction of the muta-
tion (not depicted). To add a relevant second mutagenic event, 
we investigated the occurrence of KRAS deregulation in a 
cohort of 60 unselected stage III–IV human ovarian carcinoma 
specimens. We found highly variable levels of KRAS mRNA 
in both metastatic and primary specimens, but all were higher 
than the very low levels of an immortalized ovarian surface 
epithelial (IOSE) cell line (Wang et al., 2006; Fig. 1 A). Most 
importantly, KRAS protein was also dramatically overexpressed 
in multiple tumors, compared with IOSE cells or HOSEpiC 
epithelial cells from healthy ovaries cryopreserved either at 
primary or passage one cultures (Fig. 1 B), indicating that, be-
yond the frequent gene amplification recently reported by 
the Cancer Genome Atlas Network (Bell et al., 2011), KRAS 
is deregulated in most advanced human ovarian cancers.
To model the constitutive activation of KRAS, we took ad-
vantage of existing LSL-K-rasG12D/+ mice (Jackson et al., 2001). 
Intrabursal delivery makes injected materials accessible to both 
the epithelial surface and the fimbriated epithelium at the in-
terphase with the oviduct (Fig. 1 C). Concurrent ablation of 
p53 and activation of oncogenic K-ras in double (p53/K-ras) 
Some excellent non-transplantable models of ovarian cancer 
are available, but mutagenic events activated during embryonic 
development result in animals that are born with premalignant 
lesions (Connolly et al., 2003; Xing et al., 2009), which compli-
cates their use for understanding tumor initiation. For instance, 
seminal studies by Clark et al. (2007), using a genetic model of 
pancreatic cancer, found immune tolerance against cancer soon 
after birth. This may reflect the distinctive physiopathology of 
pancreatic cancer but also be the result of defective immunosur-
veillance when mutations are initiated before the development 
of a mature immune system.
To understand how the evolution of the inflammatory 
microenvironment of developing aggressive ovarian cancers 
influences tumor progression, we have generated a new p53-
dependent model that recapitulates the immune populations 
of human tumors in previously healthy hosts. Our results 
show that accelerated malignant progression after a relatively 
long period of immune control is triggered by a phenotypic 
switch in expanding DC infiltrates, which can be reversed 
upon DC depletion, without specifically ablating tumor cells.
RESULTS
Generation of a p53-dependent inducible  
metastatic ovarian carcinoma
To model the immunobiology of aggressive (type II) ovarian 
cancers (Kurman and Shih, 2011), we first sought to generate 
an inducible cancer model in previously healthy adult mice, 
avoiding the initiation of carcinogenic events before the 
development of a mature immune system. For that purpose, 
Figure 1. The p53-dependent mouse 
model of ovarian carcinoma develops solid 
peritoneal tumor masses. (A) Expression of 
KRAS mRNA (normalized to GAPDH) in 17 repre-
sentative cases of stage III–IV human ovarian 
carcinomas, relative to IOSE cells (immortalized 
cells from the normal ovarian epithelial surface). 
(B) Relative protein expression of K-ras (normal-
ized to -actin) in seven randomly selected 
stage III–IV human ovarian carcinoma speci-
mens, IOSE cells, or HOSEpiC cells (healthy ovar-
ian epithelial cells cryopreserved either at 
primary or passage one cultures). (C) Injection of 
trypan blue into the bursal cavity of transgenic 
mice. (D) Intrabursal adenoviral injection in p53/
K-ras mice results in a primary solid ovarian 
tumor mass (P) with accompanying metastatic 
lesion (M). U, uterus. (E) Ascites detected in the 
peritoneal cavity of a chimeric p53/K-ras mouse 
injected with the adenovirus 50 d before.  
(F) Primary (P) and spontaneous metastatic 
masses (white arrows) in p53/K-ras mice 50 d 
after receiving adenovirus. (G) H&E of metastatic 
masses from indicated regions which appeared 
in mice 3 mo after undergoing resection of 
primary tumors at 35 d. Black arrows indicate 
tumor tissue. Bars, 100 µm. (H) p53/K-ras 
primary epithelial tumors stained for Cytokera-
tin 8 (CK8; ×100), Pan-Cytokeratin (PanCK; 
×200), smooth muscle actin (SMA; ×100); and 
Vimentin (×100). Bars, 100 µm. Brightness, con-
trast, and color balance were uniformly adjusted 
in whole individual images.
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Inducible ovarian tumors recapitulate the inflammatory 
microenvironment of human ovarian cancer
Nonreplicating adenoviral-Cre delivery in WT mice altered 
the leukocytic ovarian microenvironment only in a temporary 
manner, as the proportions of tissue-resident CD11c+ DCs 
were unchanged between 1 and 5 wk after surgical manipula-
tion (Fig. 2 A). Ovarian T cell infiltration (the other pre-
dominant leukocyte subset in healthy ovaries) was similarly 
unaffected (Fig. 2 A). However, when we performed an exhaus-
tive phenotypic analysis of the immune microenvironment of 
solid advanced p53/K-ras tumor masses, we found a relatively 
homogeneous population of CD11c+DEC205+MHC-II+ 
CD11b+CD86CD40low DCs, supporting our previous ob-
servations in transplantable models (Scarlett et al., 2009; 
Fig. 2, B and C). These populations of DCs expressing low 
levels of co-stimulatory molecules were also present in tumor 
draining LNs (DLNs) of animals with end stage tumors (Fig. 2 B). 
Most importantly, terminal tumors recapitulated the immune 
microenvironment of advanced human ovarian carcinomas, 
including a heterogeneous mix of antigen-presenting cells 
(Wilke et al., 2011). Thus, in advanced solid tumors of hu-
mans and p53/K-ras mice, the predominant leukocyte subset 
expressed phenotypic markers of bona fide DCs, including 
transgenic mice then resulted in palpable abdominal tumor le-
sions with 100% penetrance only 35 d after adenoviral admin-
istration. Tumors were found to be perfectly solid as they 
became more advanced (Fig. 1 D). In a proportion of animals 
we detected gross hemorrhagic ascites (Fig. 1 E), as well as me-
tastases at multiple peritoneal locations (Fig. 1, F and G).
Histological sections of the primary and metastatic tumor 
sites revealed a growth pattern characterized by solid masses 
comprised of malignant spindled cells with interspersed large 
anaplastic tumor cells. The neoplastic cells were immuno-
reactive for cytokeratin 8, desmin (not depicted), and smooth 
muscle actin and were negative for vimentin (Fig. 1 H). 
Patchy immunoreactivity with a pan-cytokeratin antibody 
cocktail was also noted (Fig. 1 H). Although on a morpho-
logical basis, sarcoma is a consideration, the immunohisto-
chemical staining pattern is most consistent with sarcomatoid 
ovarian carcinoma (i.e., induction of a high-grade poorly 
differentiated ovarian carcinoma with spindle cell morphol-
ogy). Together, these data indicate that concurrent p53 and 
K-ras mutations in the epithelial ovarian surface and/or fim-
briated epithelium at the interphase with the oviduct result 
in highly metastatic tumors with complete penetrance and 
short latency.
Figure 2. The inflammatory microenvironment of p53/K-ras end-stage tumors recapitulates advanced human ovarian carcinoma. (A) Quanti-
fication at the indicated time points of cells found within the ovaries of WT animals (n = 8) after receiving adenovirus intrabursally. Gated on CD45+ cells. 
(B) Expression of indicated activation markers on CD45+CD11c+ DCs taken from tumors or DLN of p53/K-ras mice. Early, 7 d after AdvCre injection;  
Advanced, mice with advanced tumors. Representative density plots of dissociated tumors from p53/K-ras mice (C) and patients with stage III–IV ovarian 
carcinoma (gated on CD45; D). (E–G) Density flow plots of dissociated tumors from individual patients with stage III–IV ovarian carcinoma. (H) Gating 
strategy (above) and isotypes (below) for Table 1. Error bars, SEM.
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Besides corresponding expression of phenotypic determi-
nants, CD45+CD11c+MHC-II+ DCs sorted from dissociated 
p53/K-ras advanced tumors and CD45+CD11chiHLA-DRhi-
Dec205int from unselected human tumor specimens responded 
to PMA and ionomycin by secreting a comparable pattern of 
proinflammatory chemokines. Those included high levels of 
CCL3 and CCL4, in addition to pro-angiogenic IL-8/KC 
(Fig. 3 A). A similar cytokine profile was found in DCs sorted 
from a transplantable mouse model of ovarian cancer (ID8-
Debf29/Vegf-A; Fig. 3 A). Together, these data indicate that 
our p53-dependent tumor model faithfully recapitulates the 
immune microenvironment of human ovarian cancer, and it is 
therefore suitable to understand its unknown dynamics.
Accelerated tumor growth after prolonged stability 
coincides with a switch in the inflammatory infiltrate
We found that, starting after day 21 after the adenovirus-Cre 
challenge, tumors accumulated progressively denser immune 
cell infiltrates (Fig. 3, B and C). Remarkably, tumor progressed 
through a prolonged equilibrium phase for 28 d, when no 
obvious macroscopic masses were detectable (Fig. 4 A, top). 
Leukocytes other than DCs in tumor-developing ovaries at 
CD11c, DEC205, and MHC-II (Fig. 2, C and D). In humans, 
the precise categorization of solid tumor-infiltrating my-
eloid leukocytes was more complicated as the result of a 
high degree of phenotypic overlap between DCs and mac-
rophages in some specimens. However, the most abundant 
leukocyte in at least a third of the specimens analyzed clearly 
lacked the monocyte/macrophage markers CD11b or CD14 
but coexpressed the DC marker CD11c (Fig. 2, E–G; and 
Table 1). These cells also maintain a high level of expression 
of MHC-II, so they cannot be alternatively defined as more 
immature myeloid-derived suppressor cells (Nagaraj and 
Gabrilovich, 2010; Fig. 2 H and Table 1). Interestingly, DCs 
in our mouse model progressively down-regulated MHC-II 
expression until 35 d, whereas DCs found within advanced 
tumors (>50 d) showed intermediate MHC-II expression. 
In contrast, the microenvironment of ascites showed the 
presence of predominant bona fide macrophages (Fig. 2 G). 
Therefore, the distinctive product of excessive myelopoiesis 
in most human ovarian cancer solid tumor masses is a leu-
kocyte with predominant phenotypic attributes of DCs, 
rather than canonical macrophages, which is recapitulated 
in our animal model.
Table 1. Flow analysis of leukocytes infiltrating solid Stage III/IV human ovarian tumors
Patients Gated on CD45 Gated on CD11c+HLA-DR+ Gated on Dec205 Gated on CD45
CD11c+ CD11c+HLA-DR+ Dec205+ Dec205 CD11b+CD14+ CD20+ CD3+
S1 Patient 1 52 30.9 39.9 61.7 28.6 1.78 30.9
S2 Patient 2 47.2 47.1 59.1 39.4 29.2 2.79 45.7
S4 Patient 3 (P) 84.7 82.2 17.2 81.2 4.9 n/a n/a
S5 Patient 3 (M) 84.8 56.3 12 76.8 15.6 n/a n/a
S6 Patient 4 12 12.3 70.3 30.1 44.5 n/a n/a
S7 Patient 5 57.1 56.5 70.3 25.8 21.5 n/a n/a
S8 Patient 6 52.8 52.4 41.3 59.9 7.04 1.78 30.9
S9 Patient 7 41.7 40 n/a n/a n/a 0.27 10.2
S10 Patient 8 28.2 6.35 n/a n/a n/a 0.013 0.49
S11 Patient 9 37.2 36.5 n/a n/a n/a 2.85 8.34
S12 Patient 10 37.1 5.4 n/a n/a n/a 0.045 1.92
Gating strategy is outlined in Fig. 2 H. n/a, insufficient material. Values are expressed as percentages.
Figure 3. DCs found within solid p53/ 
K-ras tumors display similar proinflammatory 
attributes as human tumor-derived DCs.  
(A) Quantification of cytokines and chemokines 
secreted from sorted CD45+CD11c+Dec205+C
D11b+/ cells from advanced human tumor 
specimens (n = 3) or CD45+CD11c+CD11b+ 
cells from tumors of end-stage p53/K-ras 
mice (n = 4) or ascites of WT mice bearing 
ID8-Defb29/Vegf-a tumors. (B) Proportion of 
CD45+ cells found within the ovaries of p53/
K-ras mice (n = 6) at the indicated time points 
after adenovirus injection. (C) CD45 immuno-
histochemical analysis of resected tumors 
(>50 d) ×100. Error bars, SEM. Bar, 100 µm.
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human tumor specimens (Fig. 4 D). From this critical turning 
point at 28 d, tumors started growing aggressively, and mice 
needed to be sacrificed at 60 d (Fig. 4 A). Notably, inflam-
matory infiltrates during this exponential phase predominantly 
expanded by accumulating CD11c+ cells, which outnumbered 
lymphocytes and remained the most abundant leukocytic 
subset until terminal stages (Fig. 4, A [middle], E, and F). This 
dramatic change in infiltrating leukocytes was not observed 
in WT animals, which were similarly treated with adenovirus-
Cre, and is therefore not a result of viral clearance or resolu-
tion of inflammation (Fig. 4, A [bottom], E, and F). Therefore, 
inducible p53/K-ras–dependent ovarian cancer progresses 
this stage did not significantly differ from surgically treated 
ovaries in WT mice, and they were characterized by predomi-
nant T cell infiltrates after day 7 (Fig. 4, A [bottom] and B).
Approximately 35 d after adenoviral challenge, coinciding 
with a change in the ratio of T cells versus DCs (Fig. 4, A and B), 
palpable tumors become apparent. At this time, these leuko-
cytes show predominant phenotypic determinants of the DC 
lineage, as they express DEC205 and CD11c (Fig. 4 C) as well 
as MHC-II. In contrast, these leukocytes did not express the 
macrophage marker F4/80 (Fig. 4 C) and still lacked expres-
sion of the myeloid marker CD11b (Fig. 4 E). We also found 
comparable ratios of CD11c leukocytes to T cells in advanced 
Figure 4. A change in the inflammatory microenvironment converges with the exponential growth of p53/K-ras tumors. (A) Top, images of explanted 
reproductive organs from p53/K-ras mice after receiving adenovirus. Middle and bottom, quantified flow analysis of resected tumors (red circle; primordial and 
advanced) from p53/K-ras (middle; n = 4–6) and WT (bottom; n = 6–8) animals, which received adenovirus previously. Slices represent mean percentages of 
CD45+ leukocytic infiltrates. (B) Comparative analysis of CD45+CD11c+CD11b and CD45+CD3+ cells infiltrating tumors of p53/K-ras mice at the indicated time 
points (n = 4–8). (C) Density plots of p53/K-ras tumors or WT ovaries which received adenovirus 35 d before (gated on CD45+ cells). Histogram of CD45+F4/
80+CD11c (blue) and CD45+CD11c+F4/80 (red). Numbers in the right corner are respective mean fluorescence intensity (MFI). (D) Percentage of CD45+CD11c+ 
and CD45+CD3+ cells found within stage III/IV human ovarian carcinoma (n = 7). (E and F) Quantification of flow analysis at the indicated time points of ovaries 
from p53/K-ras (n = 4–6) or WT (n = 6–8) mice after adenovirus injection. Error bars, SEM. *, P < 0.05; **, P < 0.001; ***, P < 0.0001; ns, no significance).
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we performed ELISPOT analysis with T cells sorted from 
mice developing early tumors. As early as at day 7 of tumor 
progression, sorted splenic T cells specifically reacted to tumor 
antigen presented by immunocompetent DCs by proliferat-
ing and secreting IFN- (Fig. 5 B, left). Importantly, these 
responses were specific for tumor antigens and not the ade-
novirus because they were absent or significantly diminished 
when T cells were sorted from WT (non–tumor-bearing) 
mice identically inoculated with intrabursal adenovirus-Cre 
(Fig. 5 B). Differential tumor-specific responses indicative 
of cytolytic T cells (Granzyme B ELISPOT analysis) were 
also observed between WT and transgenic mice using T cells 
sorted from DLNs (renal; Fig. 5 C), with corresponding 
differences in proliferation in response to tumor antigens 
(Fig. 5 C) and IFN- ELISPOT analysis (Fig. 5 D). Im-
portantly, these data indicate that advanced tumors remain 
immunogenic because all lysates used were from late tumors 
(early tumors are microscopic). In these experiments, T cells 
through a state of equilibrium that keeps tumor expansion in 
check for the first 4 wk, followed by a phase of aggressive 
growth that coincides with a dramatic switch in the signature 
of tumor-infiltrating leukocytes.
Early anti-tumor immunity is abrogated  
during aggressive malignant expansion
Notably, antibody-mediated depletion of CD8+ T cells dra-
matically accelerated aggressive malignant expansion and en-
hanced tumor burden compared with control mice, which 
did not develop any extra-ovarian masses at this temporal 
point and grew smaller primary tumors (Fig. 5 A). Tumor 
progression in our model therefore both supports and 
illustrates the cancer immunoediting hypothesis, whereby 
tumor growth can be controlled by the immune system until 
tumor cells escape, producing symptomatic cancers (Dunn 
et al., 2002; Koebel et al., 2007). To identify whether pri-
mordial tumor lesions truly elicit specific immune responses, 
Figure 5. Reduced adaptive immunity dur-
ing accelerated tumor growth. (A) Representa-
tive images of differential tumor burden (primary 
plus metastatic growth) in mice challenged with 
intrabursal adenovirus-Cre that received de-
pleting anti-CD8 (-CD8) versus isotype control 
(iIgG) antibodies at days 2, 5, 12, and 19  
(n = 4/group). (B) Left, ELISPOT analysis of IFN- 
produced by FACS-sorted CD45+CD11bCD11c 
SSClowCD8+/CD4+ T cell splenocytes incubated with 
tumor pulsed BMDCs (10:1). Spleens are from 
either WT or p53/K-ras (early) animals that received 
adenovirus-Cre intrabursally 7 d before (n = 5 
mice/group; two independent experiments). 
Middle, quantified proliferation of sorted T cell 
splenocytes from early tumor-bearing p53/K-ras 
or WT animals in response to BMDC-presented 
tumor antigens (n ≥ 5 mice/group; two indepen-
dent experiments). Right, representative histo-
gram of CFSE dilution in this experiment. (C) Left, 
ELISPOT analysis of Granzyme B (GZB) produced 
by CD45+CD11bCD11cSSClowCD8+/CD4+  
T cells FACS sorted from DLNs (renal) from the 
same mice, after incubation with tumor pulsed 
BMDCs (10:1). Middle, quantified proliferation  
of these lymphatic T cells in response to BMDC-
presented tumor antigens. (D) Percentage of  
IFN- spots produced by CD45+CD11bCD11c
SSClowCD8+/CD4+ T cells sorted from the DLN  
of either WT mice that received adenovirus 7 d 
before, or p53/K-ras advanced tumor-bearing 
mice. Normalized to the number of spots pro-
duced by sorted DLN T cells from day 7 (early) 
tumor-bearing mice, which is considered 100% 
(n ≥ 4 mice/group; pooled from two independent 
experiments). (E) Left, ELISPOT analysis of IFN- 
produced by CD45+CD11bCD11cSSClowCD8+/
CD4+ T cells sorted from the DLN of p53/K-ras animals that received adenovirus-Cre intrabursally either 7 d (early) or >50 d (advanced) before. Middle, quantified 
proliferation of sorted T cells from the same mice in response to BMDC-presented tumor antigens (n = 3 mice/group; three independent experiments, total). Right, 
representative histogram of CFSE dilution in this experiment. Error bars, SEM. *, P < 0.05. Data points on scatter plots represent individual donors for spleens and 
experimental replicates for pooled DLN. Horizontal bars, SEM. Two independent experiments for all, unless otherwise specified.
JEM Vol. 209, No. 3 
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Immunostimulatory antigen-presenting cells in primordial 
tumor lesions are replaced by immunosuppressive DCs  
in advanced ovarian cancer
The cancer immunoediting hypothesis has recently evolved to 
include a role for tumor-induced immunosuppression in ac-
celerated tumor growth (Schreiber et al., 2011). However, the 
relative contribution of specific tolerogenic mechanisms in in-
dividual tumors remains unknown. To determine how pheno-
typic changes in tumor microenvironmental leukocytes drive 
the transition from equilibrium to accelerated tumor growth 
and influence anti-tumor T cell unresponsiveness, we first ana-
lyzed the immunostimulatory potential of CD11c+ DCs sorted 
from the DLNs of primordial (day 7) tumor lesions (Fig. 6 A). 
In agreement with the quantifiable anti-tumor immunity tak-
ing place at this time, we found that DCs from early tumor-
bearing mice, in the absence of exogenous antigen, induced 
measurable expansion in tumor-reactive T cells taken from 
sorted from early tumor-bearing mice reacted against 
BMDCs pulsed with lysates of tumor cells derived from 
advanced (>60 d) specimens. However, T cells sorted from 
the DLNs of advanced (>50 d) tumor-bearing mice pro-
duced significantly fewer IFN- spots in response to the 
same antigens (Fig. 5, D and E, left). T cell unresponsive-
ness at advanced stages was further confirmed by dimin-
ished proliferative responses in response to the same tumor 
antigens (Fig. 5 E, middle and right). Because DCs pulsed 
with cells derived from advanced tumors induced signifi-
cant proliferative responses in early tumor-associated T cells, 
these data demonstrate that tumor-specific T cells become 
intrinsically less responsive during advanced malignant 
progression. Therefore, T cell–dependent tumor-specific im-
mune responses are elicited from a very early stage after 
tumor initiation, but they are abrogated during the course 
of the disease.
Figure 6. Tumor-resident DCs are transformed from immunostimulatory to immunosuppressive during tumor progression. (A) Left, CD3+ T cells 
were obtained from spleens of advanced tumor-bearing p53/K-ras animals, and then added to cultures containing BMDCs (10:1) which were previously 
pulsed with lysed tumor cells. 5 d later, sorted (nonpulsed) CD45+CD11c+ DCs from the DLNs or tumors (tumor-infiltrating DCs; TIDCs) were co-cultured 
with the tumor-specific CD3+ T cells, after CFSE labeling (10:1). Right, percentage of proliferated T cells which were cultured with sorted DCs from the DLN 
of mice with advanced tumors or animals with primordial tumors (early; received adenovirus 7 d before) or DCs from advanced tumors (B). (C) ELISPOT 
analysis of the responses induced by CD45+CD11c+ DCs, sorted from the spleens of early and advanced tumor-bearing mice, and directly incubated with tumor-
reactive T cells, obtained as in A. (D) Tumor-specific CD3+ T cells were obtained as in A, and then added to culture wells, which contained tumor pulsed 
BMDCs (1:1). Either sorted CD45+CD11c+CD11b+/ DCs or unpulsed BMDCs were added to these cultures making a 1:1:1 ratio (T cell/pulsed BMDC/sorted 
DC/BMDC). (E) Left, proliferation indices of T cells in response to the addition of tumor infiltrating DCs (TIDCs) or BMDCs. Right, representative histogram of 
CFSE dye dilution. (F) Left, proliferation indices of T cells in response to the addition of BMDCs or DLN DCs sorted from mice with early or advanced tumors. 
Right, representative histogram of CFSE dilution. n = 4 mice/group. BMDC cultures were done in quad- or quintuplicate. Even stronger differences were 
obtained using all tumor-pulsed BMDCs (not depicted). Error bars, SEM. Data points on scatter plots represent experimental replicates for pooled DLN or 
tumors. Horizontal bars, SEM. *, P < 0.05. Representative of at least two independent experiments in all panels (n = 3–4 mice/group).
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strong (immunosuppressive) Arginase activity in CD11c+ DCs 
sorted from advanced solid tumors, which was comparable to 
their CD11b+CD11c macrophage/MDSC counterparts but 
not in splenic leukocytes (Fig. 7 B). Additionally, we detected 
high levels of Arginase activity in CD45+CD14CD20CD3
CD11c+DEC205+ DCs sorted from three separate advanced 
human tumors, which could be reduced by incubation with 
synergistic immunostimulatory agonists (Fig. 7 C). Therefore, 
decreased expression of co-stimulatory mediators and a mix-
ture of immunosuppressive mechanisms converge in DCs from 
advanced tumors to abrogate protective immunity.
Together, our data thus far reveal an opposing function for 
tumor-associated DCs during the equilibrium versus the escape 
phase of tumor progression. To define to what extent pheno-
typically different DCs truly control tumor progression, we first 
brought double (p53/K-ras) transgenic mice to a B6 background. 
That resulted in slightly delayed tumor progression (80 vs. 
60 d until terminal disease), although tumors still developed 
with 100% penetrance. Syngeneic transgenic mice were then 
reconstituted with the BM of CD11c-DTR ITGAX mice, 
which allows selective temporary ablation of the DC compart-
ment through the administration of diphtheria toxin (Jung et al., 
2002; Zammit et al., 2005). As expected, depletion resulted in 
significantly lower proportions of ovarian resident CD11c+ DCs 
(Fig. 8 A) within 24 h, compared with chimeric mice which 
received PBS. Notably, CD11c+ DC depletion immediately 
before tumor challenge accelerated tumor development, 
because 75% of mice receiving diphtheria toxin grew pal-
pable tumors within 35 d, compared with only 25% control 
mice (Fig. 8 B). Furthermore, a single DC depletion 7 d after 
tumor challenge, when immunostimulatory DCs promote 
T cell–mediated anti-tumor immunity, resulted in a dramatic 
acceleration of tumor progression (Fig. 8, C [top] and D).
In striking contrast, when CD11c+ DCs were depleted at 
the beginning of the escape phase (31 d after adenoviral 
challenge in this background), elimination of DCs had the 
opposite effect and retarded tumor progression, as 100% of 
depleted animals had slower growing, smaller tumors (Fig. 8, C 
animals with advanced tumors, and therefore are overtly im-
munostimulatory (Fig. 6 A). In contrast, DCs sorted from the 
DLNs of advanced tumors (Fig. 6 A), or dissociated tumor 
masses (Fig. 6 B) of advanced tumors, induced minimal prolif-
erative T cell responses. Decreased immunostimulatory activ-
ity was further identified in splenic DCs sorted from advanced 
tumor-bearing mice, compared with mice challenged only 7 d 
earlier in more sensitive ELISPOT analysis (Fig. 6 C).
We then sought to define how early and advanced tumor 
microenvironmental DCs influence the capacity of other leu-
kocytes to drive anti-tumor immunity. Remarkably, DCs sorted 
from dissociated advanced tumors suppressed tumor-specific 
proliferation induced by immunocompetent DCs (Fig. 6, 
D and E). We again found that CD11c+ DCs sorted from ad-
vanced tumor DLNs elicited comparable immunosuppressive 
activity in multiple experiments (Fig. 6 F). In contrast, DCs de-
rived from the DLNs of nascent tumor lesions did not impair 
at all the strong expansion of tumor-reactive T cells elicited by 
tumor-pulsed BMDCs (Fig. 6 F). Together, these data indicate 
that DCs in the microenvironment of nascent tumor lesions are 
actively presenting tumor antigens to anti-tumor T cells, which 
corresponds with measurable anti-tumor immunity. In contrast, 
after tumors have started undergoing exponential growth, 
tumor microenvironmental DCs are not only incapable of 
inducing significant protective immune responses but they also 
become overtly immunosuppressive.
Phenotypically distinct DCs drive both immunosurveillance  
and immunological escape during ovarian cancer progression
Corresponding to the differential immunostimulatory capacity 
of DCs during tumor initiation and escape, we found signifi-
cantly lower levels of activating MHCII and CD40 on DCs from 
advanced stages of tumor growth (Fig. 7 A). Providing a foun-
dation for the additional immunosuppressive activity of DCs 
from exponentially growing tumors, we identified that they 
expressed higher levels of tolerogenic PDL-1, compared with 
DCs in macroscopically undetectable primordial tumor lesions 
and their DLNs (Fig. 7 A). Most importantly, we also identified 
Figure 7. Tumor-infiltrating DCs exhibit a tolerogenic phenotype. (A) Mean fluorescent intensity (MFI) of CD40, MHCII, and PD-L1 on CD45+CD11c+ 
DCs from early (ovaries 7 d after adenovirus injection) or advanced tumor masses (n = 4/group). (B) Arginase activity of CD45+CD11c+ cells sorted from 
advanced dissociated tumors and spleens of p53/K-ras animals (performed in quadruplets). (C) CD45+CD14CD20CD3CD11c+Dec205+ cells from  
three separate advanced human tumors cultured with PBS or CD40 and poly(I:C) for 24 h. Experiments were performed in duplicate. Error bars,  
SEM. *, P < 0.05. Representatives of two independent experiments are shown.
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functionally different at different phases of malignant pro-
gression and sufficient to drive both initial immunological 
control of tumor growth and accelerated tumor expansion 
after equilibrium is broken.
Tumor cell–derived PGE2 and TGF-1 promote  
the immunosuppressive activity of immunocompetent DCs
To gain some insight about microenvironmental signals pro-
moting the immunosuppressive activity of potentially immuno-
competent DCs, we quantified an array of cytokines and 
chemokines in media conditioned by cultured tumor cells 
derived from advanced tumors (UPK10 cells). We identified 
that immunosuppressive PGE2 and TGF-1, as well as IL-6, 
were secreted by tumor cells at very high levels, and their 
production could be at least partially neutralized with spe-
cific antibodies (Fig. 9 A). Notably, both tumor-derived PGE2 
and mature TGF-1 induced the up-regulation of PD-L1 
in (immunocompetent) splenic DCs sorted from day 7 tumor-
bearing mice because their blockade in tumor-conditioned 
media prevented PD-L1 overexpression (Fig. 9 B). Most im-
portantly, tumor-conditioned media promoted the immuno-
suppressive activity of splenic DCs from early tumor-bearing 
mice, which significantly impaired the strong proliferation of 
tumor-reactive T cells in response to tumor antigen presented 
by BMDCs (Fig. 9 C). Tumor-promoted immunosuppressive 
activity required both PGE2 and mature TGF-1 because 
when either was neutralized in the tumor-conditioned media, 
splenic DCs were incapable of suppressing T cell expansion 
(Fig. 9 C). Together, these results indicate that immunosup-
pressive mediators secreted by tumor cells transform po-
tentially immunocompetent DCs into immunosuppressive 
cells. This transformation, which enables the suppression of 
anti-tumor T cell–mediated responses, is in part mediated 
by PGE2 and TGF-1.
DISCUSSION
Here we have characterized the dynamics of anti-tumor im-
munity against a new genetic model of inducible ovarian can-
cer that recapitulates the immune microenvironment of human 
tumors. We found that ovarian cancer progresses through a 
prolonged period of controlled tumor growth, in which con-
trol involves the recruitment of immunostimulatory DCs that 
induce measurable T cell–mediated anti-tumor immunity as 
early as 7 d after tumor challenge. Coinciding with the expan-
sion of DCs with different (immunosuppressive) activity in the 
tumor microenvironment, tumors abrogate protective immu-
nity and start growing in an aggressive manner. Correspondingly, 
depletion of DCs, depending on the stage of tumor progres-
sion, accelerates tumor progression (early depletion) or inhibits 
exponential tumor growth (late depletion).
Previous experimental and clinical evidence shows that 
tumor growth can be kept in check for relatively long periods 
until tumor cells become edited and escape immune control, 
growing into clinically obvious cancers (Koebel et al., 2007; 
Schreiber et al., 2011). Eventual escape from anti-tumor 
immune surveillance in clinically symptomatic cancers can be 
[bottom] and D). These effects can only be attributed to 
phenotypic differences in DCs from different stages of tumor 
progression because adenoviral transduction was equally 
effective in both the absence and presence of DCs (Fig. 8 E). 
In addition, diphtheria toxin had no apparent effect on tumor 
progression, as we had previously shown in transplantable 
systems (Fig. 8 F; Huarte et al., 2008a). Together, these results 
confirm that DCs recruited to ovarian cancer locations are 
Figure 8. Distinct populations of DCs promote immunosurveillance 
and the escape phase of tumor development. (A) FACS analysis of 
dissociated ovaries from mice reconstituted with ITGAX-DTR-GFP or WT 
BM, 24 h after the i.p. administration of 6 ng/kg of diphtheria toxin.  
(B) Proportion of p53/K-ras mice reconstituted with BM from ITGAX-DTR-GFP 
mice without palpable tumors at the indicated times after administration 
of 6 ng/g of diphtheria toxin (DT) or PBS, 1 d before adenoviral injection 
(n = 6mice/group). (C) p53/K-ras mice were reconstituted with BM from 
ITGAX-DTR-GFP mice, and DCs were depleted with one dose of 6 ng/kg of 
diphtheria toxin (DT) at days 7 (n = 6 mice/group, top), or 31 (n = 10/group, 
bottom; two pooled independent experiments) after intrabursal adenovirus-
Cre. PBS (n = 10/group; two pooled independent experiments) was  
administered to control mice. (D) Representative size of advanced ovarian 
tumors in mice depleted of DCs at early versus advanced stages, compared 
with the absence of DC depletion (PBS). Error bars, SEM. *, P < 0.05;  
**, P < 0.01. (E) ITGAX-DTR (DT) or WT mice (n = 3/group) were inoculated 
intrabursally with 2.5 × 107 plaque-forming units of adenovirus express-
ing Red-Cherry, and red fluorescence was detected 4 d later. ITGAX-DTR 
mice received diphtheria toxin (6 ng/g body weight) 24 h before surgery. 
Brightness, contrast and color balance were uniformly adjusted in whole 
individual images. Bars, 100 µm. (F) Day 50 tumor growth in p53/Kras 
mice challenged with adenovirus-Cre and receiving i.p. PBS or diphtheria 
toxin (DT) 7 d later. Shown are representatives of four mice/group.
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any direct intervention on the tumor cell. Although we can-
not exclude that tumor-associated DCs also promote other 
important tumorigenic mechanisms (e.g., angiogenesis), our 
study uncovers the recruitment of immunosuppressive DCs, 
rather than loss of immunogenicity, as the principal mechanism 
driving the transition from equilibrium to expansive progression 
in ovarian cancer. In addition, our data provide a mechanistic 
rationale for targeting regulatory DCs as the characteristic 
product of the pathological myelopoiesis orchestrated by 
advanced ovarian cancers.
Importantly, similar to tumor development in adult humans, 
our model develops in healthy adult mice without active 
mutations during embryonic development. We found that 
breaking equilibrium between tumor growth and immune 
control to achieve aggressive tumor growth is significantly 
challenging in this context and is indicated by the necessity of 
two simultaneous mutation events for malignancy. In any 
case, despite the importance of p53, our work supports pre-
vious studies which demonstrate that its homozygous ablation 
does not immediately result in any obvious phenotype, and 
tumors require >7 mo to advance even after the addition of 
a second mutation, different from KRAS (Flesken-Nikitin 
et al., 2003). Overall, our results suggest that even if primordial 
tumor lesions can be established, tumor microenvironmental 
leukocytes prevent their unrelenting growth for a relatively 
prolonged equilibrium phase. Only when the inflammatory 
attributed to various complementary mechanisms. Originally, 
the cancer immunoediting hypothesis proposed the progres-
sive loss of immunogenicity by tumor cells as the fundamental 
driver of accelerated tumor growth. This implies that tumor 
immunogenicity is primarily sculpted by plastic tumor cells 
evolving to lose recognizable epitopes. More recently, the 
model has evolved to include tumor-induced immunosup-
pression as a contributor to this process, but the importance 
of individual tolerogenic mechanisms in different tumors re-
mains unclear (Schreiber et al., 2011). Our results show that 
both equilibrium and exponential ovarian cancer growth are 
driven independently by the presence of phenotypically dis-
similar DCs in the tumor microenvironment. Advanced 
tumors remain immunogenic because they induce significant 
proliferative responses in T cells from early tumors. However, 
the capacity of tumor-specific T cells to react against the same 
antigen was diminished at advanced stages, which supports 
previous observations in transplantable models (Nagaraj et al., 
2007). Concomitantly, DCs at draining lymphatic and tumor 
sites are transformed during tumor progression into a cell 
type that not only presents antigens ineffectively but also ac-
tively suppresses T cell responses. Most importantly, protective 
responses could be restored by depleting this immunosup-
pressive component, which is distinctively recruited during 
the phase when tumors spontaneously escape immune control. 
Such depletion prevents accelerated tumor growth without 
Figure 9. Tumor cell–derived PGE2 and TGF-1 promote the immunosuppressive activity of DCs. (A) Quantification of PGE2, mature TGF-1, 
and IL-6 in media conditioned by tumor cells from advanced (60 d) ovarian cancer specimens, in the presence or the absence of specific neutralizing 
antibodies. +BMDCs, BMDCs were incubated for 2 d in tumor-conditioned media before cytokine quantification; cRPMI, RPMI control media; TCmedia, 
tumor-conditioned media plus an irrelevant IgG; TCmedia+NeuAb, tumor-conditioned media plus specific neutralizing antibodies. Error bars, SEM. *, P < 0.05. 
(B) PD-L1 expression in splenic CD45+CD11c+MHC-II+ DCs sorted from mice carrying early (day 7) tumor lesions, cultured with control versus tumor-
conditioned media, in the presence or the absence of specific neutralizing antibodies. (C) Splenic DCs (spDCs) sorted from early tumor-bearing mice  
were cultured for 48 h in RPMI or tumor-conditioned media (TCMed), in the presence of neutralizing anti-PGE2 or anti–TGF-1 antibodies (NeuAb), or an 
irrelevant IgG. These cultured DCs were then incubated with tumor-pulsed BMDCs plus CFSE-labeled tumor-reactive T cells, obtained as in Fig. 6 A (1:1:1 ratio). 
Unpulsed BMDCs were added to control wells. The panel shows representative histograms of the proliferation of tumor-reactive T cells under different 
conditions. Representatives of two independent experiments are shown.
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pan Cytokeratin (AE1+AE3) 1:50 dilution, smooth muscle actin (SMA; EP184E) 
1:500 dilution, Desmin (Y266) 1:500 dilution, Cytokeratin 8 (ab59400) 1:250 
dilution, and Vimentin (RB202) 1:200 dilution were purchased from Abcam and 
immunohistochemical analyses were performed by the Dartmouth Pathology 
Translational Research Core (Lebanon, NH). For immunohistochemistry of 
leukocytes, tissues were blocked using -CD32, followed by staining with anti–
mouse biotinylated CD45 (104), MHCII (M5/114.15.2), or APC-conjugated 
Dec205 (NLDC-145; all obtained from BioLegend). Completion of immuno-
histochemical procedure was performed according to the manufacturer’s instruc-
tions (Vector Laboratories). Slides were then viewed at various magnifications 
using a fluorescence microscope (Nikon) and the NIS-Element Imaging software.
Flow cytometry. Flow cytometry was performed on a FACSCanto (BD). Sort-
ing was performed on a FACSAria sorter (BD). Anti–mouse antibodies: CD45 
(30-F11), CD11b (M1/70), DEC205 (NLDC-145), F4/80 (BM8), GR1 (RB6-8C5), 
CD3 (145-2C11), CD8 (YTS156.7.7), CD8 (53–6.7), CD4 (GK1.5), 
CD25 (PC61.5), and PDL-1 (10F.9G2; all obtained from BioLegend); and Foxp3 
(FJK-16s), CD11c (N418), and MHC-II (NIMR-4; eBioscience). Anti–human 
antibodies: CD45 (H130), DEC205 (HD30), CD11c (3.9), CD3 (OKT3), 
CD11b (ICRF44), HLA-DR (L243), CD14 (HCD14), and CD20 (2H7; all 
obtained from BioLegend). The purity of FACS-sorted populations was >90%.
Quantitative real-time PCR and sequencing. Messenger RNA copy num-
ber of various loci was assessed by quantitative real-time PCR using an Real 
Time PCR Machine (Applied Biosystems). Primers for RT-PCR experiments 
to detect human K-ras expression using SYBR green: Kras forward, 5-TGT-
GGACGAATATGATCCAACAA-3; and Kras reverse, 5-TCCTCATGTA-
CTGGTCCCTCATT-3. Primers for mouse and human GAPDH expression 
using TaqMan: GAPDH forward, 5-CCTGCACCACCAACTGCTTA-3; 
GAPDH reverse, 5-AGTGATGGCATGGACTGTGCT-3; and probe 
(FAM/TAMRA), 5-CCTGGCCAAGGTCATCCATGACAACTTT-3.
Cytokine/chemokine detection. Sorted tumor-associated cells from 
either p53/K-ras mice or Stage III–IV human ovarian carcinoma specimens 
were stimulated for 4 h with 50 ng PMA/1 µg/ml ionomycin in complete 
RPMI containing 10% FBS. Supernatants were used for cytokines and chemo-
kines using a human or mouse Custom-Plex panel cytokine assay (Bio-Rad 
Laboratories), according to the manufacturer’s instructions.
Arginase activity assay. Cells from either p53/K-ras mice (tumor and 
spleens) or Stage III–IV human ovarian carcinoma specimens were sorted. 
Quantitative colorimetric arginase determination was performed using an 
Arginase Activity detection kit (BioAssay Systems). In brief, 0.05–0.25 × 106 
cells were washed and lysed for 10 min in 50 µl of 10 mM Tris-HCl, pH 7.4, 
containing 0.15 mM pepstatin A, 0.2 mM leupeptin, and 0.4% (vol/vol) 
Triton X-100. Supernatants from lysates were then used to complete the 
assay according to the manufacturer’s instructions. For human analysis, we 
cultured cells with agonistic CP-870,893 CD40 monoclonal antibody and 
poly (I:C) as previously described (Scarlett et al., 2009). We obtained the 
CP-870,893 monoclonal antibody from Pfizer.
ELISPOT. Total or sorted cells were obtained from dissociated spleens, 
renal DLNs, or tumors of p53/K-ras or WT controls. T cells were then co-
cultured for 72 h in coated and blocked ELISPOT plates, in a 10:1 ratio 
among day 7 BMDC or sorted DC, which were previously pulsed (4 h) with 
freeze-thawed lysed UPK10 cells or resected primary tumor (10 DC/1 tumor 
cell). All cultures were maintained in complete RPMI containing 10% FBS. 
Analysis was then continued according to manufacturer’s protocol (IFN-, 
eBioscience; and Granzyme B, R&D Systems).
Immunoblotting. TRIzol reagent (Invitrogen) was used to obtain protein 
from either stage III or IV human solid tumor specimens. In brief, frozen tissues 
were cut into tiny pieces, and then added to complete RPMI where they 
were further macerated using the end of a syringe’s plunger. The dissociated 
tissues were spun and the pellets were added to TRIzol, and the completion 
infiltrate undergoes precise phenotypic and quantitative changes 
does tumor growth become exponential and thus clini-
cally apparent.
MATERIALS AND METHODS
Animals and tissues. WT C57BL/6 mice were procured from the National 
Cancer Institute or The Jackson Laboratory, under Institutional Animal Care and 
Use Committee approval. Stage III–IV human ovarian carcinoma specimens 
were procured through Research Pathology Services at Dartmouth-Hitchcock 
Medical Center under institutional approval (CPHS17702). Single cell suspen-
sions or cDNA were generated as we previously described (Huarte et al., 2008b). 
The primary mouse cell line, UPK10, was generated by culturing a mechanically 
dissociated B6 LSL-K-rasG12D/+p53loxP/loxP primary ovarian tumor mass. Tumor 
cells were passaged a total of 10× and lead to terminal tumor masses 28 d after 
i.p. injection in WT animals. HOSEpiC are epithelial cells from healthy ovaries 
cryopreserved either at primary or passage one cultures (ScienCell Research).
Generation of transgenic mice. To generate the LSL-K-rasG12D/+p53loxP/loxP 
model, we used Krastm4Tyj and Trp53tm1Brn mice (Jackson et al., 2001; Jonkers 
et al., 2001), obtained from the NCI Mouse Models of Human Cancers 
Consortium. For the indicated experiments, mice were brought to a 
C57BL/6 background.
Chimera generation and antibody-mediated depletion. BM cells (10 × 
106) isolated from ITGAX DTR-GFP mice were injected intravenously into B6 
K-rasG12D/+p53loxP/loxP after undergoing lethal doses of gamma irradiation, as we 
previously described (Huarte et al., 2008a). Mice were checked for complete re-
constitution by identifying GFP+CD45+CD11c+ cells in peripheral blood 6 wk 
after reconstitution. ITGAX-DTR (DT) or WT mice (n = 3/group) were inoc-
ulated intrabursally with 2.5 × 107 plaque-forming units of adenovirus expressing 
Red-Cherry (Gene Transfer Vector Core, University of Iowa).
CD8 T cells were depleted through intraperitoneal administration of rat 
anti–mouse CD8 antibodies (clone# YTS 169.4; BioXCell), 2 d before in-
trabursal administration of 500 µg adenovirus-Cre. Injections were repeated 
at days 5, 12, and 19 (250 µg each). Control mice received a rat IgG2b iso-
type control (clone# LTF-2; BioXCell).
Proliferation and suppression assays. For T cell proliferation assays, day 7 
BMDCs, generated as previously described (Scarlett et al., 2009), were cultured 
overnight with either freeze-thawed lysed UPK10 or dissociated primary tumors. 
BMDCs were added to cultures of CFSE (Invitrogen)-labeled T cells at a 10:1 
ratio and were analyzed 3 d later by flow cytometry. For DC proliferation assays 
(Fig. 6 A, schematic), Pan T cell isolation (Miltenyi Biotec) was performed using 
spleens taken from p53/K-ras animals with advanced (>50 d after AdvCre 
injection) tumors. CD3+ T cells were then cultured for 4–5 d with tumor-
pulsed BMDCs as described at a 10:1 ratio to generate tumor-specific T cells. 
Tumor-specific T cells were then CFSE labeled and added to V-bottom 96-well 
plates which contained sorted DCs (10:1 ratio). Cultures were analyzed by flow 
cytometry 5 d later. For the suppression assay (Fig. 6 C, schematic), tumor-pulsed 
BMDCs were added to CFSE-labeled tumor-specific T cells (1:1), followed by 
addition of unpulsed BMDCs or sorted DCs (1:1:1 ratio) in V-bottom 96-well 
plates. Analyses were performed 3 d later.
Neutralization assays. PGE2 (Cayman Chemical) and mature TGF-1 and 
IL-6 (both eBioscience) were quantified by ELISA in media conditioned 
for 2 d by >90% confluent UPK10 tumor cells. When indicated, neutralizing 
antibodies against mouse PGE2 (7 µg/ml; 2B5; Cayman Chemical), TGF-1 
(5 µg/ml; 2Ar2; Abcam) or IL-6 (4 µg/ml; PeproTech) were added to the 
media. Goat anti–mouse IgG (Jackson ImmunoResearch Laboratories, Inc.) 
was used as a control.
Histological analysis. For frozen tissue, organs of mice were collected and em-
bedded in Tissue-Tek OCT. For paraffin-embedded tissue, organs were fixed in 
4% formaldehyde overnight at 4°C. Fixed sections (8 µm) were then made from 
frozen or paraffin-embedded tissue blocks. For analysis of tumor histological type, 
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to a nitrocellulose membrane, blocked, and incubated with the indicated 
primary Ab. Immunoreactive bands were developed using horseradish 
peroxidase–conjugated secondary Abs (Bio-Rad Laboratories) and chemi-
luminescent substrate (GE Healthcare). Human KRAS, -actin, and -tubulin 
were detected using a mouse anti–human mAb (clone no. ab55391), rabbit 
anti–human (ab8227), and goat anti–human (ab21057) antibodies, respectively 
(all from Abcam).
Statistical analyses. Differences between the means of experimental groups 
were analyzed using the Mann-Whitney or the 2 test. Survival was analyzed 
with the Log-rank test, both using Prism 4.0 software (GraphPad Software). 
Proliferation indices, defined as the mean number of cell divisions that the re-
sponding cells underwent, were calculated using FlowJo software (Tree Star).
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